Royalty Report: Drugs, Dermatology, obesity – Collection: 257618

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Dermatology
  • obesity
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 257618

License Grant
This agreement is for commercialization rights of the compound.

Upon the exercise of the Scenario II Option, The Swiss Licensee shall take over the lnvestigational New Drug Application with the FDA or such other application filed with any other Regulatory Authority and Licensee shall be responsible for the overall development and regulatory filings for the Product in the Territory.  Subject only to the option to co-promote under Scenario II Licensee and its Affiliates shall have the exclusive rights for the Commercialization of the Compound or Product and Licensor shall grant Licensee an exclusive license under the Licensor Technology.

Upon the exercise of the Scenario III Option. In the event that Licensee does not exercise its Scenario II Option, Licensor will consider the results of the Phase II Clinical Trial and may elect to commence Phase III Clinical Trials for the Product within twelve months of the delivery of the final Phase II Clinical Trial report to Licensee.   Subject only to the option to co-promote under Scenario Ill Licensee and its Affiliates shall have the exclusive rights for the Commercialization of the Compound or Product and Licensor shall grant Licensee and exclusive license under the Licensor Technology.

License Property
Compound shall mean the compound currently identified as -094 or isomers or epimers thereof and any metabolites and salts thereof.   -094 corresponds to 2-(2-methylimidazol-l-methyl)pyridine fumarate. It has the molecular formula C10H11N3C4H4O4.
Field of Use
The Field of Use shall mean application to all conditions, disorders and diseases in humans.  The studies include blood pressure, dermatology and obesity.

IPSCIO Record ID: 257487

License Grant
The Licensors of Switzerland grant an exclusive license, with the right to sublicense with the prior written consent of Licensors, such consent not to be unreasonably withheld, under the Licensors Patents and Know-How, to develop, use, make and have made Compound and Product in the Field of Use and in the Territory.

Subject to the Scenario II Option and Scenario III Option and the Co-Promotion Option being exercised by Licensor,  Licensee shall have an exclusive license to Commercialize the Compound and Product, with right to sublicense without consent.

License Property
Compound shall mean the compound currently identified as NDD-094 or isomers or epimers thereof and any metabolites and salts thereof.   -094 corresponds to 2-(2-methylimidazol-l-methyl)pyridine fumarate. It has the molecular formula C10H11N3C4H4O4.

VSF-173 is a compound for the treatment of excessive sleepiness, for which we expect to begin a Phase II trial in the second half of 2006

Field of Use
The Field of Use shall mean application to all conditions, disorders and diseases in humans.  The studies include blood pressure, dermatology and obesity.

IPSCIO Record ID: 223128

License Grant
The Swiss Licensors hereby grant to Licensee an exclusive license, with the right to sublicense with the prior written consent of Licensors, such consent not to be unreasonably withheld, under the Licensor Patents and Licensor Know-How, to develop, use, make and have made Compound and Product in the Field of Use and in the Territory.
License Property
Product shall mean a formulated pharmaceutical product containing the Compound or Back-up Compound as an active ingredient and packaged for the use by the ultimate consumer.

Compound shall mean the compound currently identified by Licensors as NDD-094 or isomers or epimers thereof and any metabolites and salts thereof and more particularly described Licensor Patents shall mean those Patents Controlled by Licensor claiming Compound, Product, or their metabolites or any formulation of Compound, processes, uses and intermediates of the foregoing.

Licensor Know-How shall mean any proprietary or nonproprietary information specific to the Compound or Product within the Field of Use and of a confidential nature necessary or useful for the manufacture, preparation or development of the Compound or Product Controlled by Licensors during the term of this Agreement and shall include, without limitation, data, knowledge and information., including chemical, stability, pharmacological, toxicological, pre-clinical, clinical and manufacturing data, samples, documentation, analytical standards, and gene expression data.

Patents – United States
5,635,521 – Imidazolylmethyl-pyridines
5,856,343 – Imidazolylmethyl-pyridines used for senile dementia

Field of Use
This agreement pertains to the drug industry relating to the Field of Use that shall mean application to all conditions, disorders and diseases in humans.

Iloperidone is an atypical antipsychotic for the treatment of schizophrenia.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.